Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...
Mirum Pharmaceuticals' promising pipeline and strong financials make it an attractive buy in the competitive PBC space. Click ...
Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...
Gilead Sciences’ seladelpar has been recommended by the European Medicines Agency’s human medicines committee to treat the ...
Zacks.com on MSN18d
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX GainsIt was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.
Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) recommended approval of seladelpar.
For Gilead, which generated $28.3 billion in revenue over the last twelve months with a robust 77.8% gross profit margin, seladelpar represents another potential growth driver. The treatment, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback